Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM04755 in Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer
NCT02191761Phase 1Completed
- Sponsor
- Biosplice Therapeutics
- Start
- Jun 2014
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SM04755 in colorectal cancer (CRC), gastric cancer (GC), hepatocellular carcinoma (HCC) and 1 more, sponsored by Biosplice Therapeutics. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jun 2014; status: completed.
02
Drugs
SM04755
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)hepatocellular carcinoma (HCC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02191761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02191761.